Prospective pharmacovigilance studies should evaluate whether concomitant administration of NLRP3 inhibitors (e.g., colchicine) or IL-1β-neutralizing biologics could mitigate FGF21-associated gout flare risk in predisposed individuals. The gene discussed is NLRP3; the disease is gout.